Nutrition and Pharmacological Algorithm for Oncology Patients Study

Study summary

Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease the suffering and distress associated with eating during cancer treatment and improve the quality of life of patients by implementing an algorithm utilizing nutrition intervention and appetite stimulants.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedDexamethasone and Dronabinol

Plus 2 other study approaches.

Who it may be forOncologic Complications · Quality of Life

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 16, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Montefiore Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 4
Sponsor: Montefiore Medical Center
Interventions being studied: Drug: Dexamethasone; Drug: Dronabinol; Drug: Mirtazapine; Behavioral: Nutrition Intervention

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Study topics

Survivorship and quality of life→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Patients with a diagnosis of head/neck, lung, pancreatic cancer, or metastatic cancer from any solid tumor 2. Planned, ongoing, or recently treated patient (within the past 30 days) with chemotherapy, immunotherapy, and/or intravenous targeted biologic therapy 3. No previous use of appetite stimulants 4. All patients must sign study specific informed consent prior to being included in the study 5. No contraindication to appetite stimulants

Reasons someone may not be able to joinExclusion criteria

1. Patient \<18 years old 2. Contraindication to appetite stimulants

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Montefiore HospitalThe Bronx, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 16, 2022. Always confirm current availability with the study team.

View original record ↗